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Silver nanoparticles (AgNPs) have cytotoxic properties via generation of reactive oxygen 
species which are involved in the generalized sickness behavior of the host including fever 
and lethargy among others.  The aim of the present study was to investigate the impact of 
AgNPs on the ability of rat peripheral blood mononuclear cells (PBMCs) to release fever 
mediating factors after stimulation with lipopolysaccharide (LPS). Body temperature and 
motor activity of the Wistar rats were measured by biotelemetry system.  Rat PBMCs were 
stimulated with LPS and after that, the cells were washed and incubated alone or with 
AgNPs.  The final supernatants were injected intraperitoneally.  The levels of endogenous 
pyrogens such as interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) released 
from the PBMCs into the final supernatants were also estimated.  The results indicated that 
injection of the supernatants from the cells stimulated with LPS induced fever and inhibited 
motor activity.  These effects were potentiated by the presence of AgNPs during the final 
incubation.  The presence of the AgNPs also resulted in significant increases in levels of 
endogenous pyrogens.  The augmentation of fever in the rats by the AgNPs treatment of the 
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Nanotechnology is the general term for the creation, manipulation and application of 
structures in the nanometer size range.  Nanoparticles are defined as structures having 
dimensions of roughly 1-100 nm, whose unique properties enable their novel application [1].  
The range of applications of nanoparticulate as drug carriers includes the treatment of all 
diseases of major public health concern, such as cancer, diabetes and severe infections [2].  
Generally, nanoscale drug delivery systems have the ability to improve the pharmacokinetics 
and increase biodistribution of therapeutic agents to target organs [3].  Moreover, this 
technology allows for release of the drug in a controlled manner and increases bioavailability 
by facilitating drug transport across critical and specific barriers, including blood-brain 
barrier [4].  Nowadays, nanotechnology has developed numerous types of nanoparticulate 
drug carriers, such as liposomes, micelles, dendrimers, nanotubes, nanoshells, nanoemulsions 
and metallic nanoparticles such as silver nanoparticles [5, 6, 7]. 
Presently, silver nanoparticles (AgNPs) are emerging as a new generation of antibacterial 
agent, which has been used in medical applications (e.g. wound dressings, surgical instruments 
and bone prostheses) [8, 9].  Among metallic nanomaterials including copper, zinc, titanium, 
magnesium, gold and silver, AgNPs have proved to be most effective in killing bacteria, 
viruses and other eukaryotic microorganisms [10].  These nanostructures can act on the living 
cells at the nano-level resulting not only in the biologically beneficial effects, but also may 
provoke some undesirable perturbations.  AgNPs have a large surface area per unit mass and 
this property makes nanosystems very reactive in the cellular environment [11].  In 
consequence, AgNPs have cytotoxic properties via a generation of the reactive oxygen 
species (ROS) and induction of the intracellular oxidative stress [12].  It is well known that 
ROS are involved in the generalized sickness behaviour of the host including fever and 
lethargy, and these activities are related to the induction of the signal transduction leading to 
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the upregulation of the transcription factors such as nuclear factor kappa B (NF-κB) [13].  
Intracellular upregulation of NF-κB is necessary for the induction of the synthesis of the 
pyrogenic and pro-inflammatory cytokines [14].  However, to the best of our knowledge, 
there is no research focusing on the pyrogenic and sickness behaviour properties of the silver 
nanoparticles. 
Fever is a common response to infection, inflammation, injury and trauma.  It is a regulated 
rise in body temperature (Tb) that results from un upward resetting of variables controlling 
the set-point of thermoregulation [15].  An increase of Tb during fever has several advantages 
over infections: inhibition of bacterial growth, increase in bactericidal activities of 
neutrophils and macrophages, T cells proliferation and differentiation, B cells proliferation 
and the production of antibodies or stimulation of acute-phase protein synthesis [16, 17].  The 
initial step in the cascade of events leading to fever is believed to be a stimulation of a large 
number of various immune types of cells, i.e., monocytes, macrophages and neutrophils by 
exogenous stimuli, called exogenous pyrogens [18].  These stimuli are represented by 
bacteria wall components such as lipopolysaccharide (LPS) or lipoteichoic acid, viral 
components such as double-stranded RNA and bacterial DNA (CpG-DNA) [19, 20].  
Stimulation of immune cells by any of these various pyrogens leads to synthesis of pro-
inflammatory mediators, called endogenous pyrogens.  The most important mediators of 
fever and other symptoms of sickness are cytokines such as interleukin-1β (IL-1β), IL-6, 
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) [15, 18, 21-24].  Since it has been 
known that macrophages stimulated with LPS release the pyrogenic factors [25, 26], and 
there are data showing that AgNPs may influence some immunologic activities, we have 
studied the effect of AgNPs on the releasing of these fever mediating factors by the PBMCs 
stimulated in vitro with LPS.  From our findings, we conclude that AgNPs can potentiate 
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production of pyrogenic factors by PBMCs that have been already stimulated with LPS but 




Male Wistar rats [Strain: Wistar Crl: WI(Han)] (8-12-wk-old, 200-250 g) were purchased 
from the Experimental Medicine Centre at the Medical University of Bialystok and allowed 
to acclimatize for 10 days before the start of any experiments.  The rats were housed in 
individual polycarbonate cages in a room maintained at constant relative humidity (60 ±5%), 
temperature (24 ±1°C), and with a 12-hr light-dark period.  All rats had ad libitum access to 
standard rodent laboratory food (Labofeed B, Morawski, Poland) and filtered drinking water.  
The Local Bioethical Committee for Animal Care approved all procedures (Permission # 
4/2011). 
 
Body temperature (Tb) and motor activity measurement 
The Tb of rats was monitored (with accuracy of ±0.1
o
C) using battery-operated miniature 
biotelemeters (PhysioTel
®
 model TA10TA-F40, Data Sciences International, USA) 
implanted intra-abdominally as described previously [27].  The animals were anaesthetized 
with a ketamine/xylazine mixture (87 and 13 mg kg-1, respectively) injected intramuscularly.  
An incision was made in the abdomen and a telemetry transmitter was placed into the 
abdominal cavity for the continuous monitoring of the physiologic variables.  All surgical 
procedures were done at least one week before the start of experiments.  Motor activity of the 
rats was measured by changes in position of the implanted transmitter over the receiver 
board.  These result in a change of the signal strength detected by the receiver and recorded 
as a "pulse" or "count" of the activity. 
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Rat PBMCs fraction preparation 
Blood was collected from anesthetized rats by cardiac puncture into the solution of 
ethylenediamine tetraacetic acid (EDTA, MP Biomedicals; cat. no. 160054).  The whole 
blood was diluted 1:1 (vol/vol) with phosphate buffered saline (PBS, pH 7.4) at room 
temperature.  A 5 mL portion of this blood was then carefully layered onto 3.5 mL of the 
separation medium (Ficoll-Paque Plus, Amersham Biosciences; cat. no. 17-1440-02) in a 10 
mL centrifuge tube and centrifuged (35 min, 400 x g, room temperature).  The PBMCs 
fractions were isolated, pooled, and then washed twice in 2 vols PBS before being suspended 
at 10
6
 cells mL-1 in complete RPMI 1640 containing 2 mM L-glutamine (Sigma-Aldrich; cat. 
no. R5886) and heat-inactivated 10% fetal bovine serum (FBS), 100 g streptomycin mL-1, 
and 100 U penicillin mL-1 (PAA Laboratories GmbH, Cölbe, Germany). 
 
Culture conditions and stimulation 
Freshly isolated PBMCs were seeded into 60-mm petri dishes (at 10
6
 cells mL-1 - in 10 mL 
volume) and then pre-incubated for 1 hr at 37°C in a 5% CO2 incubator maintained with a 
95% humidity.  All culture conditions were identical in each protocol.  The 10
6 
cells were 
stimulated with LPS (1 µg mL-1) for 4 h.  Then, the cells were washed twice in PBS (1000 x 
g, 5 min), suspended in the fresh pathogen-free RPMI medium 1640 and incubated for the 
next 2 h with AgNPs (25 µg mL-1; assigned as experimental incubation; cells+LPS+AgNPs).  
In separate experiments, the 10
6
 cells were stimulated only with AgNPs (25 µg mL-1) for 2 h 
and not treated with LPS (assigned as reference incubation I; cells+AgNPs).  In the separate 
cultures the cells were stimulated for 4 h with LPS (1 µg mL-1; assigned as reference 
incubation II; cells+LPS).  Control cells were incubated with pyrogen-free saline for 4 h as a 
control vehicle (control incubation; cells + saline).  After completion of all variants of the 
stimulation, cells were collected from the plates by using a scraper and washed twice in PBS 
(1000 x g, 5 min).  Then, the cells were suspended in fresh pathogen-free RPMI medium 
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1640 and incubated for 2 h.  The final supernatants were aspirated, centrifuged for 5 min at 
1500 x g and stored at -50
o
C.  All procedures resulted in a greater than 95% viable PBMCs in 
the suspension by trypan blue dye (Sigma-Aldrich; cat. no. T6146) exclusion assay.  LPS 
derived from Escherichia coli (0111:B4, Sigma Chemicals; cat. no. L-2630) and AgNPs 
(Sigma Aldrich; cat. no. 576832) were used for the stimulation of the cells.  LPS was diluted 
in a pyrogen-free saline.  Serum-free RPMI 1640 medium were used in the case of cell 
cultures incubated with AgNPs to avoid aggregation.  Before exposure, a stock solution of 
AgNPs (1 mg mL-1) was prepared aseptically in the serum-free RPMI 1640 medium 
followed by bath sonication (Sonic 1, POLSONIC, Poland) for 10 min at room temperature to 
avoid nanoparticles agglomeration.  Prior to administration to the cells, the final 
nanoparticles suspension was vortexed  for 15 seconds. 
Cell viability - MTT assay 
MTT assay was performed to estimate toxic effects of AgNPs on the PBMCs.  The cells were 
seeded into 96-well plates at a density of 5x10
4
 cells/well and stimulated with AgNPs (5, 
12.5, 25, 35 and 50 µg mL-1) for 2 hr in the same culture condition as described above.  After 
exposure to AgNPs, the culture media was removed and replaced with fresh media (RPMI 
medium 1640 without phenol red; 100 μL/well).  The cells were thereafter treated with 25 μL
of MTT (3-[4,5-dimethylthiazol-3-yl]-2,5-diphenyl tetrazolium bromie; Sigma Aldrich; cat. 
no. M5655, 5 mg mL-1 in PBS) and incubated at 37 °C for 4 hr.  Non-treated cells were used 
as control. After that, the formazan crystals were dissolving with 100 μL of dimethyl 
sulfoxide (Sigma Aldrich; cat. no. D2438).  Then absorbance at two wavelengths (570 nm 
and 630 nm) was recorded using ELISA reader (Multiskan FC; Thermo Scientific, USA).  All 
absorbance values were corrected against blank wells which contained growth media alone.  
All measurements were done in duplicate in three independent experiments. 
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Silver nanoparticles analysis by scanning electron microscopy (SEM) and Dynamic Light 
Scattering technique (DLS) 
The size and shape of the dry AgNPs powder were analyzed by the scanning electron 
microscopy (SEM - Quanta 3D FEG; Carl Zeiss, Göttingen, Germany) in the secondary 
electron (SE).  The working parameters used were: high voltage - HV = 30.0 kV and working 
distance - WD = 10.1 mm.  It is a high-resolution microscope, which allows studying of the 
structure of nanomaterials.  On the basis of the resulting image the diameters of AgNPs were 
measured using the program ImageJ (Java-based image processing program developed at the 
National Institutes of Health; USA).   
Dynamic Light Scattering method (DLS - Zetasizer Nanoseries S4700,Malvern Instruments, 
Worcestershire, UK) was used to determine the size distribution profile of nanoparticles in 
the solution (serum-free RPMI 1640 medium).  For this, the 1 mg mL-1 stock AgNPs 
suspension in the deionized water was sonicated for 15 minutes in a water bath sonicator 
(Sonic 1, POLSONIC, Poland) before further dilution in serum-free culture medium to a final 
concentration of 25 μg mL-1.  Then, the final nanoparticles suspension was vortexed  for 15 
seconds, sonicated for 15 minutes in a water bath sonicator and finally, it was vortexed again 
for 15 seconds immediately before DLS analysis.  The samples were loaded into quartz 
microcuvette and three measurements were performed, for which the mean result was 
recorded. 
Elemental analysis of the AgNPs was performed using the energy-dispersive X ray 
spectroscopy (EDX - Quantax 200; Carl Zeiss, Göttingen, Germany). 
Cytokine assays 
The final culture supernatants were analyzed for the release of IL-1β, IL-6 and TNF-α from 
the PBMCs.  The levels of these cytokines were determined by a standard sandwich ELISA 
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kit from R&D Systems (cat. no. R6000B, RLB00, RTA00, respectively) according to the 
manufacturer’s instructions.  Colorimetric changes in the assays were detected using 
Multiskan FC ELISA plate reader (Thermo Scientific, USA).  The sensitivity of the IL-1, 
IL-6 and TNF- kits were, respectively, less than 5 pg mL-1, 21 pg mL-1 and less than 5 pg 
mL-1. 
In vivo treatment protocols  
Separate groups of animals were injected intraperitoneally (ip) at 8:00 am with 2 mL of the 
supernatants from the control, reference I, reference II, or experimental incubation systems.  
An additional set of control rats was injected IP with RPMI 1640 vehicle while another set 
was injected IP with AgNPs suspended in RPMI 1640 at 25 µg mL-1. 
Statistical analysis 
All values are reported as means ± standard error mean (S.E.M.) and were analyzed by 
analysis of variance (ANOVA) followed by the Student’s t-test with the level of significance 
set at P<0.05.  For the Tb and motor activity measures, recordings were taken at 5-min 
intervals.  For data presentation, these 5-min temperature and motor activity recordings were 
then pooled into 20-min or 5-hr averages, respectively. 
Results 
Characterization of silver nanoparticles 
Dry powder of AgNPs from Sigma Aldrich were analyzed by the scanning electron 
microscopy.  According to the SEM micrographs, shapes of the particles were approximately 
spherical, with a tendency to agglomerate (Figure 1A).  The diameters of AgNPs measured 
using the program ImageJ on the basis of the resulting image indicated that nanoparticles had 
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a diameters in the range of 32-98 nm.  Moreover, analysis of 100 nanoparticles showed an 
average particle size of 67.6 [± 17] nm (data not shown).  In agreement with data obtained 
from the Sigma Aldrich, SEM images of the anhydrous AgNPs samples showed primary 
particle sizes of < 100 nm diameter 
DLS technique was used to determine the size distribution profile of nanoparticles in the 
solution (serum-free RPMI 1640 medium).  The obtained results indicated that the tested 
colloid contained nanoparticles with the sizes of 298 [± 160] nm (92%), 46 [ ±9] nm (4,2%) 
and 4660 [± 869] nm (3,8%) (Figure 1B).  




Viability percentage measured by MTT assay on PBMCs exposed to 5, 12.5, 25, 35 and 50 
μg AgNPs mL-1 for 2 h was dose-dependent (Figures 2).  The results demonstrated that 
AgNPs at a dose of 5, 12.5 and 25 μg mL-1 during 2 h incubation did not have a toxic effect 
on PBMCs in comparison to non-treated cells.  On the other hand, the higher dose (35 and 50  
μg mL-1) of AgNPs were 24 [± 2] % and 44 [± 3] % more cytotoxic (P < 0.05 and P < 0.01 
respectively) after 2 hr incubation.  Therefore, a dose of 25 μg mL-1 was selected for 
experimentation. 
Figure 2 
Changes in the body temperature after injections of the tested supernatants  
Rats are nocturnal animals revealing low daytime and high nighttime Tb and motor activity.  
Animals injected with AgNPs in RPMI showed normal Tb circadian rhythms (12-hr average 
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daytime Tb of non-treated rats = 37.25 [± 0.09]°C and those treated with AgNPs in RPMI = 
37.24 [± 0.09]°C; data not shown).  Injection of supernatants from the control or reference 
incubation I cultures gave rise to 12-hr average Tb values of, respectively, 37.22 [± 0.10]°C 
and 37.18 [± 0.09]°C) (Figure 3).  This indicated that neither regimen led to a culture medium 
that could induce alterations in rat Tb.  The occasional transient increase in rat Tb at 08:00 
am (injection time) was most likely due to the process of handling the rats itself.  During 




As can be seen in Figure 4, injection of the reference incubation II (cells+LPS) supernatants 
induced increases in rat Tb that started to increase 2.5 h post-injection and lasted 3 hr (10:30-
13:30).  On the other hand, administration of the supernatants from the experimental 
incubation (cells+LPS+AgNPs) augmented this elevation in Tb.  These rats displayed a fever 
that started to increase 2 hr after the injection but now lasted for 5 hr (10:00-15:00).  Among 
rats that received the reference incubation II material, the 3-hr average Tb was 37.29 [± 
0.10]°C; whereas in rats treated with supernatants from the experimental incubation system, 
the 5-hour average Tb was 37.81 [± 0.14]°C, the levels significantly different from one 
another (P < 0.001). 
Figure 4 
 
A presence of AgNPs in the cultures did not affect the lethargy subsequently associated with 
the treatment of PMBC with LPS alone 
As shown in Figure 5, the motor activity of rats (from 10:00-15:00) that had been injected 
with culture supernatant of the reference incubation II or experimental incubation was 
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significantly lower than that in rats that received medium from the control incubation (1.18 ± 
0.17 counts).  The values associated with the reference incubation II or experimental 
incubation, i.e., 0.81 [± 0.08] and 0.68 [± 0.13] counts, respectively, did not significantly 
differ (P = 0.36). 
Figure 5 
 
AgNPs augment secretion of IL-1β into culture of PBMCs stimulated with LPS but have no 
effect on release of IL-6 and TNF-α 
Stimulation of PBMCs with LPS only (reference incubation II) provoked release of cytokines 
into the culture medium (Figure 6).  Levels of IL-1β in control (cells + saline) and reference 
incubation I (cells + AgNPs) samples were similar (64 [± 2] and 67 [± 4] pg mL-1, 
respectively) (Figure 6A).  With reference incubation II cultures (cells + LPS), the IL-1 
level reached 201 [± 13] pg mL-1; P < 0.001 between respective groups).  The addition of 
AgNPs in the experimental incubation system (cells + LPS + AgNPs) further augmented this 
release of IL-1β to 378 [± 10] pg mL-1 (Figure 6A; P < 0.001 between the two groups).  In 
contrast, a presence of AgNPs did not influence LPS-induced elevations of IL-6 and TNF-α 
(Figure 6B and 6C). 
Incubation of the PMBCs with AgNPs (reference incubation I; cells+AgNPs) itself increased 
the level of IL-6 to 161±14 pg mL-1 compared to the control value of 41±7 pg mL-1 
(cells+saline).  In contrast, LPS stimulated IL-6 release to a level of 580 [± 18] pg mL-1 (P < 
0.001).  The addition of AgNPs did not significantly alter this LPS effect (level now of 603 
[± 13] pg mL-1; P=0,36; Figure 6B). 
TNF- release by PBMCs in the control (cells+saline) and reference I incubations 
(cells+AgNPs) was at levels of 10 [± 7] and 12 [± 1] pg mL-1, respectively (Figure 6C).  LPS 
alone significantly stimulated TNF- secretion (reference II incubations; cells+LPS) to 454 
13 
[± 17] pg mL-1 (P < 0.001).  The addition of AgNPs in the incubation did not significantly 




Silver nanoparticles were characterized by SEM and DLS technique.  It can be seen that the 
results obtained from SEM analysis and the DLS method are not comparable.  The size of the 
dry AgNPs powder analyzed by the SEM (67.6 [±3]nm; Figure 1A) was significantly smaller 
in comparison to the diameters of nanoparticles measured by DLS technique (298 [±160]nm 
and 46 [±9]nm (4,2%); Figure 1B).  Moreover, the DLS analysis demonstrated the diameter 
sizes, which were considerably larger than of that indicated in product’s information (< 100 
nm; Figure 1B).  Because of the fact, that the SEM technique allowed to determine the 
primary size and morphology of AgNPs only in dry samples, the size characterization of 
AgNPs in RPMI 1640 medium had to be carried out using DLS method.  It is known that 
nanoparticles size and agglomeration are dependent on the type of suspension media.  For 
example, Murdock et al. [28] showed that the diameters of AgNPs size of 80 nm increased 
from 250 nm in deionized water to 743 nm in serum-free RPMI 1640 medium.  Similarly, 
other also demonstrated that in the DLS technique larger aggregates were observed in the 
deionized water or in the RPMI 1640 medium in comparison to the results from the SEM and 
transmission electron microscopy (TEM) methods.  The discrepancy may be attributed to 
particle aggregation in the DLS measurements while SEM or TEM allow to latitude for 
eliminating clumps of particles [29, 30].  
Presented data demonstrate that silver nanoparticles (~300 nm) added to the culture of LPS-
stimulated blood mononuclear cells enhanced the LPS-induced production of the pro-
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inflammatory cytokine IL-1β, and the supernatants from that culture, when administered to 
rats, a elicited significantly greater febrile responses than that of supernatants derived from 
the cell culture stimulated with LPS alone.  Moreover we have shown that neither the sterile 
suspensions of AgNPs nor supernatants from PBMCs co-cultured with AgNPs are pyrogenic.  
It also appeared that AgNPs possessed an in vitro potential to stimulate release of IL-6 from 
PBMCs, however it did not potentiate an LPS-induced releasing effect on IL-6.  Since the 
supernatants derived from cells+AgNPs culture did not evoke a febrile response in the rats 
(Figure 4), we conclude, therefore, that the enhanced fever in the rats injected with 
cells+LPS+AgNPs culture supernatants was due to the greater concentration of IL-1β rather 
than IL-6, although the two cytokines, as was mentioned earlier, are considered equally the 
most potent endogenous pyrogens.   
Our studies correspond to the data presented by Zampronio et al. [25], who showed that rat 
peritoneal macrophages stimulated with LPS (10 µg mL-1) for 30 min released the pyrogenic 
factors into the supernatants.  Injections of supernatants, which showed pyrogenic properties, 
also provoked lethargy measured as a decrease in motor activity of rats.  Depression of motor 
activity is correlated with the increase in Tb (fever) of rats.  Both reactions belong to the non-
specific symptoms, which are known as the sickness behavior that accompany responses of 
the host to infection and inflammation [31].   
There are data demonstrating that AgNPs have the inflammatory activities.  Carlson et al. 
[32] showed in in vitro studies that rat alveolar macrophages exposed to 5, 10 and 25 μg 
AgNPs mL-1 (sizes of 15, 30 or 55 nm) for 24 h produced significant levels of pro-
inflammatory cytokines, such as IL-1β and TNF-α.  On the other hand, some authors suggest 
that AgNPs can also have the anti-inflammatory properties.  Tian et al. [33] showed that 
treatment of murine infected burns with AgNPs increased the rate of healing and decreased 
scarring.  It has been accompanied by the increased expression of anti-inflammatory 
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cytokines such IL-10 and reduced expression of IL-6.  Santoro et al. [34] demonstrated that 
murine RAW264.7 monocyte/macrophage cell line stimulated with AgNPs (20, 40 and 60 µg 
mL-1) for 4, 8 or 12 h did not induce pro-inflammatory cytokines expression, such as IL-1β 
or IL-6.  The explanation of these different results needs further examination.  One could 
consider the characteristics of the AgNPs themselves, such as surface properties (charge, and 
specific area) or morphology (shape and crystal structure) [35].  The size of nanoparticles, 
type of the cells and the time of in vitro stimulation could also have had effect on the 
production of pro-inflammatory cytokines. 
Recently, there is an increasing number of reports indicating potential toxic characteristics of 
AgNPs, which is associated with inflammatory potential of necrotic or apoptotic cell death by 
the nanoparticles.  Orlowski et al. [36] using an in vitro model of mouse peritoneal 
monocytes (RAW 264.7 cell line) and mouse keratinocyte cell line 291.03C showed that 
AgNPs were toxic in concentration-dependent manner.  However, necrosis were the 
dominating cell death mechanism in monocytes while in keratinocytes Orlowski et al.
observed rather apoptosis than necrosis.  Moreover, murine keratinocytes exposed to AgNPs 
underwent apoptosis characterized by a high activity of caspase-9 – an indicator of 
mitochondrial apoptotic pathway.  In contrast, murine monocyte RAW 264.7 cell line showed 
more necrosis than apoptosis and high activity of caspase-1 – an enzyme involved in 
inflammatory reactions.  These results indicate that effects of AgNPs depend on the type of 
exposed cells. [36].  Park et al. [37] using an in vitro model of mouse peritoneal monocytes 
(RAW 264.7 cell line) proposed a ‘Trojan – horse mechanism’ of AgNPs cytotoxicity.  After 
exposure to commercially produced AgNPs powder, cell viability decreased, which is 
correlating with the increasing sub G1 fraction and it indicates for cellular apoptosis.   
Moreover, AgNPs decreased intracellular glutathione level, increased nitric oxide (NO) 
secretion and increased TNF-α in protein and gene levels [37].  It is well known, that 
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nanoparticles induce toxicity through oxidative stress and inflammation by generating 
reactive oxygen species (ROS) in cells.  Glutathione protects cells against exogenous and 
endogenous toxins, including ROS and it is the primary antioxidant responsible for 
maintaining the reducing intracellular microenvironment that is essential for normal cellular 
function and viability [38].  Moreover, NO is a signaling molecule that plays a key role in the 
pathogenesis of inflammation.  It gives an anti-inflammatory effect under normal 
physiological conditions.  On the other hand, NO is considered as a pro-inflammatory 
mediator that induces inflammation due to over production in abnormal situations [39].  
Finally, TNF-α is also known to stimulate several signaling pathways leading to 
inflammation, apoptosis and tissue degradation [40].  Summarizing, phagocytosis of AgNPs 
stimulate inflammatory signaling through the generation of ROS, followed by the activated 
cells induced secretion of TNF-α.  Finally, the increase of TNF-α cause damage of cell 
membrane and apoptosis [37].  
As described above, it is known, that AgNPs may have significant toxic effects on cells that 
primarily occur in a dose-dependent manner.  However, there have been also reports on the 
size dependence of the cellular toxicity of AgNPs.  The size of nanoparticles plays a critical 
role in the cellular uptake processes from the intracellular membrane to the nuclear 
membrane [41].  Kim et al. [42] using an in vitro model of mouse preosteoblast cell line 
(MC3T3-E1) and rat adrenal medulla derived cell line (PC12) demonstrated that AgNPs with 
the sizes of approximately 10, 50, and 100 nm have the potential to exert cytotoxic effects.  
Moreover, the smallest sized AgNPs (10 nm size) had a greater apoptotic effect against the 
MC3T3-E1 cells than other-sized AgNPs (50 and 100 nm).  Other researchers have also 
suggested the higher cytotoxicity of smaller particles compared to larger ones, which was 
related to the amount of ROS generated at the relatively larger surface area of small 
nanoparticles [43, 44].  The MTT assay has shown that tested AgNPs at a dose of 25 μg mL-1 
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during 2 h incubation did not have a toxic effect on PBMCs (Figure 2).  Moreover, the results 
of DLS technique showed that our nanoparticles were the size of  about 300 nm.  The 
findings of scientists suggested that particle features such as size and agglomeration status as 
well as the type of cells may contribute to nanoparticles biological impact [45].  Auffan et al. 
[46] demonstrated that single or smaller particles could pose a greater hazard compared to 
larger particles or agglomerates/aggregates.  Furthermore, Lankoff et al. [47] showed that the 
aggregates of AgNPs size about 300 nm at a dose 10 and 50 μg mL-1 did not significantly 
effect on the viability of  the following cell lines: A549 (human lung epithelial cell line), 
HepG2 (human liver cell line) and THP1 (human monocyte cell line) during 24 h incubation.  
Moreover, the THP1 cells showed significantly higher binding/uptake for less agglomerated 
particles.  Because of the fact, that in our studies we incubated PBMCs with the agglomerated 
AgNPs size about 300 nm only for 2 h, we concluded that the tested aggregates of AgNPs 
had to large sizes in RPMI 1640 medium to be internalized by monocytes, induce necrosis 
and thus, inflammatory reaction.  For these reason, we summarize that our AgNPs augment 
releasing of pyrogenic factors by PBMCs stimulated with LPS and moreover, these 
phenomenon does not affect cell viability.   
It is well known, that both polymorphonuclear leucocytes (basophils, eosinophils and in 
particular neutrophils) as well as PBMCs (lymphocytes and monocytes/macrophages) are 
capable of synthesizing and releasing a variety of pro-inflammatory mediators, including 
cytokines [48].  However, in our experiments from all leukocytes, we have decided to 
stimulated only PBMCs with LPS and/or AgNPs.  Firstly because, Dinarello et al. [49] 
showed that although neutrophils can synthesize and release endogenous pyrogen, it appeared 
that macrophages show in this respect 100 fold higher capacity.  Moreover, the presence of 
neutrophils may have a suppressive effect on monocytes to release pro-inflammatory 
cytokines [49].  Secondly, recent studies have described cytokine production by granulocytes 
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with results that are controversial.  Several groups have detected production of pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF-α [50, 51] and others reported no IL-6 
production [52].  Similarly, the measured TNF-α secretion could not be confirmed by other 
authors [53].  Summarizing, PBMCs population seems more suitable for research on the 
production of pro-inflammatory cytokines than granulocytes. 
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Figure 1.  Scanning electron microscopy (SEM) image of silver nanoparticles (a scale 
illustrating 500-nm size is presented in the Figure 1A) in relation to the size distribution 
profile of nanoparticles in the solution (serum-free RPMI 1640 medium) measured by the 
Dynamic Light Scattering technique (DLS) (B). 
Figure 2.  Cell viability of AgNPs treated cultures relative to the controls.  PBMCs were 
exposed to 5, 12.5, 25, 35 and 50 μg AgNPs mL-1 for 2 hr.  Values are expressed as 
means ±S.E.M. of three experiments.  Asterisk indicates significant difference compared 
to the controls (*P<0.05,**P<0.01). 
Figure 3.  Changes of body temperature over time (h) of rats treated ip at 8:00 am 
(arrowhead) with the  supernatants from control incubation (cells+saline; open circles) 
and the supernatants from reference incubation I (cells+AgNPs; close triangles) in 
comparison to non-treated animals (close circles).  Values are means ± S.E.M. at 20-min 
averages (n indicates sample size in a respective group).  
Figure 4.  Changes of body temperature over time (h) of rats treated ip at 8:00 am 
(arrowhead) with the supernatants from reference incubation II (cells+LPS; open 
diamonds) and the supernatants from experimental incubation (cells+LPS+AgNPs; close 
diamonds) in comparison to Tb of animals administrated ip with the supernatants from 
control incubation (cells+saline; open circles).  Values are means ± S.E.M. at 20-min 
averages (n indicates sample size in a respective group). 
Figure 5.  Changes in motor activity of rats shown in Figure 2.  Values are means ± 
S.E.M. at 5-h averages from 10 am to 3 pm (n indicates sample size in a respective group 
of rats).  Asterisk indicates significant difference (**P<0.01). 
Figure 6.  Concentration of IL-1β (pg mL-1 A), IL-6 (pg mL-1; B) and TNF-α (pg mL-1; 
C) in the final supernatants aspirated after: control incubation of PBMCs with pyrogen-
26 
 
free 0.9% saline (vertical bars), reference incubation I of cells with AgNPs (black 
column), reference incubation II of cells with LPS (horizontal bars) and experimental 
incubation (cells+LPS+AgNPs; white column).  Values are expressed as means ±S.E.M. 
of three experiments.  Asterisk indicates significant difference (**P<0.01,***P<0.001). 
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